You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A device containing immobilized chelator to remove aluminum from TPN solutions

    SBC: ALKYMOS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Delivery of Sleeping Beauty Transposons to Dog Liver for Gene Therapy

    SBC: DISCOVERY GENOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of Discovery Genomics, Inc. is to develop the Sleeping Beauty transposon system for human gene therapy. To achieve this to treat hemophilia, we must be able to direct uptake and long-term expression of therapeutic genes in targeted tissues such as the liver. Only one method of plasmid delivery has been effective for high-level gene expression ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Detection of Biofilm Bacteria using GloBac

    SBC: SUBC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The microbiologic diagnosis of infected joint anthroplasty is inaccurate using current techniques. Dr. Robin Patel has developed and validated a new technique that samples microorganisms in biofilms on the surface of ex planted orthopedic implants. This technique yields biofilm microorganisms suspended in solution; currently these organisms are detected using p ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  4. New anti-complement therapy to reduce reperfusion injury: Phase II

    SBC: ENDOPROTECH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Tissue and organ transplantation procedures save and/or improve the lives of hundred of thousands of patients annually in the US. The goal of this research is to develop a local anti-complement therapy for donor organ e x vivo application that will reduce complement-induced injury to the vascular endothelium. An unavoidable consequence of transplantation (allog ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Neuroprotectants for TBI

    SBC: STALLION THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): There are no FDA approved pharmacological therapies for the acute treatment of traumatic brain injury (TBI) that mitigate damaging neurological effects. However, the potential for effective pharmacological intervention exists in that a majority of post-traumatic degeneration results from pathochemical and pathophysiological cascades of secondary events that oc ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  6. PET and SPECT Ligands for Imaging Apoptosis

    SBC: IMMUNOCHEMISTRY TECHNOLOGIES, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): PET and SPECT Ligands for Imaging Neuronal Apoptosis Abstract: Activation of the intracellular caspase cascade is a well understood signaling mechanism that results in apoptosis. The identification of apoptotic events i n vivo has important applications for detecting cell death induced by disease, injury, therapeutics, or normal tissue development and different ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Potential anti-relapse drugs: a plant genomics approach

    SBC: NAPROGENIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcohol-induced neurodegeneration and the consequent dementia are important therapeutic targets in alcoholism. However, because alcohol-induced neurotoxicity has different mechanisms during the presence of alcohol and during its withdrawal, these are difficult targets for pharmacotherapy. Based on preclinical research, two types of neuroprotective compound, po ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Small Molecule Drug Therapy for Parkinson's Disease

    SBC: NEOCYTEX BIOPHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The total cost of caring for Parkinson's disease is about 25 billion per year in the United States. There is an urgent and unmet need for an effective treatment for the patients who have suffered debilitating loss of n eurons and motor function. Development of neuroregeneration therapy is an important goal because neurdegenerative diseases disable and kill mil ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Stem Cell Graft Engineering to Treat Sickle Cell Disease

    SBC: REGENEREX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is a genetic abnormality of red blood cells (RBC) that affects over 70,000 people in the United States, or approximately 1 in every 500 African-Americans. With current therapies, the mortality in the United States is 50% by age 40. SCD is a chronic, debilitating disease associated with frequent painful crises, acute chest syndrome, st ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting drug delivery nanoparticles to sites of inflammation

    SBC: POTENTIA PHARMACEUTICALS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a nanoparticle-based drug delivery system for use in the treatment of dry age-related macular degeneration (AMD). AMD is the leading cause of blindness for individ uals over fifty-five years of age that live in the industrialized world, affecting approximately 10 million people in the US and as many as 30 ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government